硫基-氨酸在 De Novo 标特异性共价结合剂的宏环中进行核糖体内结合
Yawen Yang1, Pei Liu2, Xi-Yang Cui2
1State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, P. R. China.
Journal of the American Chemical Society
|July 19, 2025
概括
包含4-硫基-l-氨酸 (FSY) 的宏环为共价药物开发提供了一种新方法. 这项创新增强了向治疗,特别是在放射性核酸治疗中,改善了瘤选择性和保留性.
科学领域:
- 医学化学
- 药物发现
- 生物技术
背景情况:
- 在共价药物开发中,宏环具有高特异性和低毒性.
- 目前的方法,如mRNA显示,通过关注囊残留物而受到限制,限制了可向的蛋白质多样性.
研究的目的:
- 开发一种用于创建多样化的共价宏环库的新方法.
- 探索4-硫基-l-氨酸 (FSY) 在新药查中的潜力.
- 在向放射性核酸治疗中评估含FSY的宏环的疗效.
主要方法:
- 将4-硫基-l-氨酸 (FSY) 结合到宏环中.
- 针对人类α-血栓和纤维细胞激活蛋白的多种共价宏环库的新选.
- 在体内研究中将含FSY与放射性核素化剂结合.
主要成果:
- 鉴定具有强大的抑制活性 (低纳米范围) 的新型共价宏环.
- 与非共价结合剂相比,含FSY的具有不同的解离特征.
- 在向放射性核酸治疗中,结合的瘤选择性吸收和长期保留被证明是增强的.
结论:
- 为新发现含FSY的宏环建立了一个强大的平台.
- 这种方法扩大了对各种生物医学应用的共价药物开发的范围.
- 基于FSY的宏环具有针对性的放射性核酸治疗的显著潜力.
相关概念视频
2° Amines to N-Nitrosamines: Reaction with NaNO2
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
Vicinal Diols via Reductive Coupling of Aldehydes or Ketones: Pinacol Coupling Overview
Wilhelm Rudolph Fittig discovered the pinacol coupling reaction in 1859. It is a radical dimerization reaction and involves the reductive coupling of aldehydes or ketones in the presence of hydrocarbon solvent to yield vicinal diols.
C–C Bond Formation: Aldol Condensation Overview
Aldol condensation is an important route in synthetic organic chemistry used to generate a new carbon–carbon bond under basic or acidic conditions. The aldol condensation reaction presented in Figure 1 constitutes an aldol addition reaction followed by the dehydration process.
Drug Metabolism: Phase II Reactions
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme activation, sulfur...
Phase II Reactions: Miscellaneous Conjugation Reactions
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...


